Cellectis (NASDAQ:CLLS) Stock Crosses Below 50-Day Moving Average - Should You Sell?

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) shares passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.46 and traded as low as $1.33. Cellectis shares last traded at $1.33, with a volume of 63,678 shares traded.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Wall Street Zen lowered Cellectis from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Barclays dropped their price target on Cellectis from $5.00 to $4.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th.

Cellectis Stock Down 2.9%

The company has a fifty day simple moving average of $1.46 and a 200-day simple moving average of $1.53. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The firm has a market cap of $73.93 million, a P/E ratio of -1.02 and a beta of 2.92.

Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03). The business had revenue of $12.03 million during the quarter, compared to the consensus estimate of $12.71 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. On average, equities analysts anticipate that Cellectis S.A. will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Cellectis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. OLD Mission Capital LLC purchased a new stake in Cellectis during the first quarter valued at approximately $31,000. Wells Fargo & Company MN increased its holdings in shares of Cellectis by 103.4% in the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after acquiring an additional 12,500 shares during the period. Acadian Asset Management LLC increased its holdings in shares of Cellectis by 132.9% in the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock valued at $55,000 after acquiring an additional 26,461 shares during the period. Millennium Management LLC acquired a new stake in shares of Cellectis in the 4th quarter worth $962,000. Finally, B Group Inc. acquired a new stake in shares of Cellectis in the 4th quarter worth $5,547,000. 63.90% of the stock is owned by institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.